Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 3,066 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Injection Clear all
Withdrawn Not applicable Interventional

Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.

NCT05106192
View directory record Official record
Conditions
Mycosis Fungoides of Skin (Diagnosis), Cutaneous T-cell Lymphoma, Non Hodgkin Lymphoma, Lymphomatoid Papulosis, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Follicular
Interventions
Med-Jet Injector, Triamcinolone Acetonide, Bexarotene 1% Top Gel, Nitrogen Mustard, Conventional syringe
Device · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 20, 2026, 5:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of GENEVAX-HIV, a Possible Vaccine

NCT00002232
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
APL 400-003
Biological
Lead sponsor
Wyeth-Lederle Vaccines
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 5:23 AM EDT
Terminated Phase 4 Interventional Results available

A Study Comparing Continuous Sciatic Nerve Block to Single Shot Sciatic Nerve Block

NCT01615939
View directory record Official record
Conditions
Fracture of Foot
Interventions
Bupivacaine, Ropivacaine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Oct 20, 2026, 5:23 AM EDT
Completed Phase 3 Interventional Results available

A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma

NCT00097981
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Thalidomide, Dexamethasone, DOXIL
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
58
States / cities
Fountain Valley, California • Greenbrae, California • La Verne, California + 55 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 20, 2026, 5:23 AM EDT
Terminated Phase 2 Interventional

Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy

NCT00742612
View directory record Official record
Conditions
Intracranial Embolism, Cerebral Thromboembolism, Carotid Stenosis
Interventions
ARC1779 Injection, Placebo (normal saline)
Drug
Lead sponsor
Archemix Corp.
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Hackensack, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2010 · Synced Oct 20, 2026, 5:23 AM EDT
Not listed Phase 2 Interventional

Evaluating the Safety and Effect of abobotulinumtoxinA in the Gastrocnemius Muscle to Improve Equinus and Plantar Fasciitis Pain

NCT03978234
View directory record Official record
Conditions
Plantar Fasciitis, Plantar Fasciitis, Chronic, Plantar Fasciitis of Both Feet
Interventions
AbobotulinumtoxinA 300 UNT
Drug
Lead sponsor
University Foot and Ankle Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 20, 2026, 5:23 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy of an Antibody to CCR5 in Individuals With HIV Who Are Not Currently on Antiretroviral Therapy

NCT00114699
View directory record Official record
Conditions
HIV Infections
Interventions
CCR5mAb004
Drug
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Fort Lauderdale, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 20, 2026, 5:23 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Marcaine Use in Laparoscopic Gynecological Surgery

NCT01861665
View directory record Official record
Conditions
Post-operative Pain
Interventions
Marcaine 0.25%.
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 20, 2026, 5:23 AM EDT
Completed Phase 3 Interventional Results available

OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

NCT03180307
View directory record Official record
Conditions
Ovarian Cancer
Interventions
OTL38, near infrared camera imaging system, laparotomy
Drug · Device · Procedure
Lead sponsor
On Target Laboratories, LLC
Industry
Eligibility
18 Years to 85 Years · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
10
States / cities
Phoenix, Arizona • Tucson, Arizona • Duarte, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 20, 2026, 5:23 AM EDT
Completed Phase 2 Interventional

Navigator vs Standard Needle Injection for Hip

NCT02066844
View directory record Official record
Conditions
Hip Pain Etiology Unknown
Interventions
Celestone, Lidocaine
Drug
Lead sponsor
Cartiva, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Oct 20, 2026, 5:23 AM EDT
Completed Phase 1 Interventional

A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation

NCT02685098
View directory record Official record
Conditions
Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease, Vascular Disease, Arterial Occlusive Disease, Arteriosclerosis, Atherosclerosis, Cardiovascular Disease, Pathologic Processes, Orthopedic Procedures, Amputation
Interventions
Allogeneic bone marrow derived mesenchymal stem cells
Biological
Lead sponsor
Indiana University
Other
Eligibility
40 Years to 90 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 20, 2026, 5:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients

NCT02041195
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Setmelanotide, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Oct 20, 2026, 5:23 AM EDT
Completed Not applicable Interventional

Effect of Reparel Knee Sleeve With Knee Injection

NCT04859764
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Reparel knee sleeve, Corticosteroid injection, Placebo knee sleeve
Device · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 20, 2026, 5:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of the Medial Parapatellar Knee Injection Technique

NCT00712972
View directory record Official record
Conditions
Osteoarthritis, Accuracy of Intraarticular Needle Placement
Interventions
Not listed
Lead sponsor
Oklahoma State University Center for Health Sciences
Other
Eligibility
5 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 17, 2009 · Synced Oct 20, 2026, 5:23 AM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration

NCT02401945
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
DE-120, Aflibercept
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
50 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Phoenix, Arizona • Bakersfield, California • Walnut Creek, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 20, 2026, 5:23 AM EDT
Terminated Phase 2 Interventional

Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy

NCT00726544
View directory record Official record
Conditions
Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura
Interventions
ARC 1779 Placebo, ARC1779 Injection
Drug
Lead sponsor
Archemix Corp.
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
7
States / cities
Chicago, Illinois • Indianapolis, Indiana • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2009 · Synced Oct 20, 2026, 5:23 AM EDT
Terminated Phase 3 Interventional Results available

Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee.

NCT03988023
View directory record Official record
Conditions
Severe Osteoarthritis of the Knee
Interventions
Ampion, Saline
Biological · Drug
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Oct 20, 2026, 5:23 AM EDT
Terminated Phase 2 Interventional Results available

Effects of Botox in Obstructed Defecation Syndrome

NCT02160288
View directory record Official record
Conditions
Obstructed Defecation Syndrome (ODS)
Interventions
Botulinum Toxin-A, Normal Saline
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 20, 2026, 5:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Safety and Effectiveness of Juvéderm® VOLUMA XC Injectable Gel for Cheek Augmentation

NCT00978042
View directory record Official record
Conditions
Mid-facial Volume Deficit Related to Aging
Interventions
Juvéderm® VOLUMA XC
Device
Lead sponsor
Allergan
Industry
Eligibility
35 Years to 65 Years
Enrollment
345 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 20, 2026, 5:23 AM EDT
Completed Phase 1 Interventional

Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors

NCT02827968
View directory record Official record
Conditions
Solid Tumors
Interventions
KN035
Drug
Lead sponsor
3D Medicines (Sichuan) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Lafayette, Indiana • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 20, 2026, 5:23 AM EDT
Completed Not applicable Interventional Results available

Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients

NCT02321527
View directory record Official record
Conditions
Breast Cancer
Interventions
Perflutren Protein-Type A Microspheres Injectable Suspension, Contrast-Enhanced Ultrasound (CEUS), Biopsy + Radioactive Seed Placement, Phone Call
Drug · Device · Procedure + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 20, 2026, 5:23 AM EDT
Active, not recruiting Phase 3 Interventional

Microfragmented Adipose Tissue Compared to Saline Injection for the Treatment of Knee Osteoarthritis

NCT06121882
View directory record Official record
Conditions
Knee Osteoarthritis, Osteo Arthritis Knee
Interventions
Microfragmented Adipose Tissue derived using the Lipogems® System, Saline Injection
Device · Drug
Lead sponsor
Lipogems International spa
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
16
States / cities
Phoenix, Arizona • Encinitas, California • La Mesa, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 20, 2026, 5:23 AM EDT
Completed Phase 2 Interventional

A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy

NCT04656561
View directory record Official record
Conditions
Geographic Atrophy
Interventions
ANX007, Sham comparator
Drug · Other
Lead sponsor
Annexon, Inc.
Industry
Eligibility
50 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
45
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 20, 2026, 5:23 AM EDT
Terminated Phase 2 Interventional Results available

Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344)

NCT00711087
View directory record Official record
Conditions
Neurogenic Bladder Dysfunction Nos, Spinal Cord Injury
Interventions
BOTOX-A, Saline injection
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 20, 2026, 5:23 AM EDT